Guggenheim upgraded Biogen to Buy from Neutral with a price target of $350, up from $270.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biotech Alert: Searches spiking for these stocks today
- RBC says CMS clarity on Leqembi reimbursement should reduce Biogen overhang
- Biogen price target lowered to $340 from $344 at RBC Capital
- Biogen price target raised to $330 from $325 at Canaccord
- Biogen price target lowered to $321 from $325 at Needham